SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009950
Filing Date
2023-05-15
Accepted
2023-05-15 17:04:09
Documents
75
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrxp-20230331x10q.htm   iXBRL 10-Q 986396
2 EX-10.1 nrxp-20230331xex10d1.htm EX-10.1 28777
3 EX-31.1 nrxp-20230331xex31d1.htm EX-31.1 15353
4 EX-31.2 nrxp-20230331xex31d2.htm EX-31.2 15417
5 EX-32.1 nrxp-20230331xex32d1.htm EX-32.1 7085
6 EX-32.2 nrxp-20230331xex32d2.htm EX-32.2 6407
  Complete submission text file 0001558370-23-009950.txt   5224514

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrxp-20230331.xsd EX-101.SCH 48605
8 EX-101.CAL nrxp-20230331_cal.xml EX-101.CAL 33491
9 EX-101.DEF nrxp-20230331_def.xml EX-101.DEF 221463
10 EX-101.LAB nrxp-20230331_lab.xml EX-101.LAB 312598
11 EX-101.PRE nrxp-20230331_pre.xml EX-101.PRE 359668
69 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20230331x10q_htm.xml XML 760017
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38302 | Film No.: 23924043
SIC: 2834 Pharmaceutical Preparations